Base-edited CAR T-cell therapy shows promise for relapsed, refractory childhood ALL
Base-edited chimeric antigen receptor T-cell therapy is feasible for the treatment of relapsed or refractory childhood T-cell acute lymphoblastic leukemia, suggests research published in The New England Journal of Medicine.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Intracerebral polio–rhinovirus immunotherapy feasible for paediatric malignant glioma
Intracerebral recombinant polio–rhinovirus immunotherapy is feasible in children and young people with heavily pretreated, high-grade malignant glioma, suggest phase 1b trial findings published in The Lancet Child & Adolescent Health.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
‘Multihit’ gastric cancer risk from H. pylori plus cancer-predisposing variants
The presence of Helicobacter pylori alongside pathogenic variants in cancer-predisposing genes combine to increase the risk for gastric cancer, report researchers in The New England Journal of Medicine.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Haplo-SCT plus dinutuximab beta ‘feasible’ for relapsed high-risk neuroblastoma
Children with relapsed, high-risk neuroblastoma may benefit from immunotherapy with dinutuximab beta after haploidentical stem-cell transplantation, investigators write in the Journal of Clinical Oncology.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Anthracycline heart failure risk quantified for breast cancer, lymphoma patients
Patients who receive an anthracycline during treatment for breast cancer or lymphoma are more than three times as likely to develop congestive heart failure than healthy individuals, indicates a case–control study published in JAMA Network Open.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
PRIME II ‘extremely reassuring’ on radiotherapy omission in older women with early breast cancer
The 10-year data from the PRIME II trial suggest that radiotherapy after breast-conserving surgery can be omitted for women aged 65 years or older with low-risk, hormone receptor-positive early breast cancer.
iNTEGRATE fails to demonstrate significant cGVHD benefit for ibrutinib–prednisone regimen
Combining ibrutinib and prednisone for the treatment of new-onset chronic graft-versus-host disease after allogeneic haematopoietic cell transplantation does not improve patient response compared with prednisone alone, show phase 3 trial findings published in the Journal of Clinical Oncology.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Maintenance darolutamide shows promise in metastatic CRPC
Phase 2 data point to the potential of switch maintenance with darolutamide in men with metastatic castration-resistant prostate cancer that has not progressed after taxane therapy.
Sotorasib demonstrates potential for KRAS-mutated pancreatic cancer
The KRAS G12C inhibitor sotorasib has shown “promising anticancer activity” in a phase 1/2 trial of patients with heavily pretreated, metastatic pancreatic cancer harbouring the target mutation, researchers report in The New England Journal of Medicine.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
CT brain cancer risk quantified for children and young adults
The European EPI-CT study has confirmed there is a linear dose–response relationship between radiation exposure during computed tomography imaging and the risk of malignant brain tumours, in children and young adults.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
